General Procedure Kit
510(k) K960248
Active
Valid until
No expiry
FDA recalls
None ongoingDocuments
Trust
Unverified
Regulatory status
| Region | Authorization | Number | Date | Status |
|---|---|---|---|---|
| United States | FDA 510(k)SESE | NumberK960248 | Date12 Apr 1996 | StatusActive |
Recalls
-
- Terminated Z-0193-2016
Integra received an Urgent Drug Recall Notice from Hospira Inc. for their 1% Lidocaine HCL Injection, USP, 10 mg/mL, Lot 44-359-DK. Hospira Inc. is recalling vials of Lot 44-359-DK, 1% Lidocaine HCL Injection, USP, 10 mg/mLm distributed by Hospira from February 2015 to March 2015 due to a confirmed complaint of visible, partially embedded particulate within a single-dose glass teartop vial.
-
- Terminated Z-2575-2011
- Terminated Z-2576-2011
Kits contain protective wipes that may be contaminated with Bacillus cereus.
-
- Terminated Z-2079-2009
- Terminated Z-2105-2009
- Terminated Z-2082-2009
- Terminated Z-2087-2009
- Terminated Z-2104-2009
- Terminated Z-2083-2009
- Terminated Z-2101-2009
- Terminated Z-2097-2009
- Terminated Z-2089-2009
- Terminated Z-2103-2009
- Terminated Z-2095-2009
- Terminated Z-2107-2009
- Terminated Z-2096-2009
- Terminated Z-2098-2009
- Terminated Z-2106-2009
- Terminated Z-2081-2009
- Terminated Z-2100-2009
- Terminated Z-2092-2009
- Terminated Z-2102-2009
- Terminated Z-2108-2009
- Terminated Z-2086-2009
- Terminated Z-2093-2009
- Terminated Z-2090-2009
- Terminated Z-2094-2009
- Terminated Z-2080-2009
- Terminated Z-2085-2009
- Terminated Z-2088-2009
- Terminated Z-2091-2009
- Terminated Z-2099-2009
Lack of packaging seal integrity on various pain management kits may compromise sterility of contents.
-
- Terminated Z-1635-2008
Hep-Lock Flush vials included in Integra's PICC Insertion Trays contain a heparin component that has been recalled by Baxter for contaminated heparin.
Coverage
- Active
- Expiring
- Withdrawn
- Listed
- Not covered
United States — FDA 510(k) Active
Specification
- 510(k) Number
- FDA Product Code
- FMF
- Device Class
- Class II
- Regulation
- 21 CFR Part 880.5860
- Advisory Committee
- General Hospital
- FDA Decision
- SESE Substantially Equivalent